|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN immunohistochemistry was performed on 45 occurrences of endometrial neoplasia and their paired antecedent benign biopsies, along with age matched sample pairs from 167 patients who did not develop a neoplasm.
|
24662919 |
2014 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Rapamycin demonstrated activity in fresh endometrial tumor explants independent of PTEN and Akt status.
|
20863555 |
2010 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.
|
18632658 |
2008 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.
|
18563337 |
2008 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Correlation between NDRG1 and PTEN expression in endometrial carcinoma.
|
18377423 |
2008 |
|
Endometrial Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
|
17219201 |
2007 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Imprint smears were obtained from 80 fresh endometrial tumor specimens and studied immunocytochemically for the expression of PTEN, p53, and beta-catenin proteins.
|
17504383 |
2007 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
|
17924977 |
2007 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Transcriptional profiling endometrial carcinomas microdissected from DES-treated mice identifies changes in gene expression associated with estrogenic tumor promotion.
|
16804899 |
2006 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
|
16949921 |
2006 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice.
|
16402032 |
2006 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma.
|
16012720 |
2005 |
|
Endometrial Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.
|
14663583 |
2004 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Enhanced cell growth inhibition following PTEN nonviral gene transfer using polyethylenimine and photochemical internalization in endometrial cancer cells.
|
15453811 |
2004 |
|
Endometrial Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozygosity using three microsatellites (D10S215, D10S541, and D10S564) and the complete sequence analysis of PTEN exons in breast and endometrial tumor samples from the same patient were also carried out in an attempt to identify additional PTEN somatic mutations.
|
14675182 |
2003 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1.
|
12888921 |
2003 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
For these experimental purposes five main classes of experimental models are available: spontaneous endometrial tumorigenesis models in inbred animals (Donryu rats, DA/Han rats, BDII/Han rats), inoculation tumors from chunks of tumors (rat EnDA-tumor, human EnCa 101 tumor) or from inoculated tumor cell lines (rat RUCA-I cells, human Ishikawa and ECC-1 cells), developmental estrogenic exposure or chemical carcinogen exposure of CD-1 and ICR mice, transgenic approaches such as mice heterozygous regarding the tumor suppressor gene PTEN (pten(+/-)-mice) and endometrial tumor cell lines cultured under conditions promoting in vivo-like morphology and functions e.g. cell culture on reconstituted basement membrane.
|
12653669 |
2003 |
|
Endometrial Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
PTEN mutations and evolving concepts in endometrial neoplasia.
|
11801878 |
2002 |
|
Endometrial Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors.
|
11854177 |
2002 |
|
Endometrial Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias.
|
11849740 |
2002 |
|
Endometrial Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy.
|
12209607 |
2002 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
PTEN1 is frequently mutated in primary endometrial carcinomas.
|
9326929 |
1997 |
|
Endometrial Neoplasms
|
0.600 |
Biomarker
|
group |
MGD |
|
|
|